Homobispiperidinyl derivatives as liver X receptor beta agonists, compositions and their use

Patent metadata

Field	Value
Publication number	US-10752587-B2
Application number	US-201615780289-A
Country	US
Kind code	B2
Filing date	Nov 29, 2016
Priority date	Dec 1, 2015
Publication date	Aug 25, 2020
Grant date	Aug 25, 2020

Abstract

In its many embodiments, the present invention provides certain substituted bispiperidinyl compounds of the Formula (I): and pharmaceutically acceptable salts thereof, wherein ring A, ring B, R 1 , R 2 , R 3 , L, R 4 , X, Z, Li, Q and R5 are as defined herein. The novel compounds of the invention, and pharmaceutically acceptable compositions comprising a compound thereof, are useful as Liver X-β receptor (LXRβ) agonists, and may be useful for treating or preventing pathologies related thereto. Such pathologies include, but are not limited to, inflammatory diseases and diseases characterized by defects in cholesterol and lipid metabolism, such as Alzheimer's disease.

First claim

We claim:

1. A compound having the structural Formula (I):

or a pharmaceutically acceptable salt thereof, wherein:
ring A is

ring B is

L 1 - is —CH 2 —, —CH 2 CH 2 —, —C(O)—, —O—, or —S—;
R 1 is selected from the group consisting of H, methyl, and halogen;
R 2 is selected from the group consisting of H, —S(O) 2 (C 1 -C 6 alkyl), and halogen;
X is selected from the group consisting of —N— and —CH—;
Z is selected from the group consisting of N and C(R 4 );
R 4 is selected from the group consisting of H and methyl;
L is a bond and R 3 is selected from the group consisting of H, —(C 1 -C 6 )alkyl and —(C 1 -C 6 )alkyl-OH;
or, alternatively, L is a divalent moiety selected from the group consisting of —C(O)— and —S(O) 2 —;
and R 3 is —N(R N1 )(R N2 ), wherein:
R N1 is selected from the group consisting of H and —(C 1 -C 6 )alkyl; and
R N2 is selected from the group consisting of: H, —(C 1 -C 6 )alkyl, —O—(C 1 -C 6 )alkyl, —OH, halogen, —CN, and —(C 1 -C 6 )alkyl which is substituted with 1 or 2 groups independently selected from the group consisting of:
—OH, halogen, —CN,
—NH 2 , —NH(C 1 -C 6 )alkyl, —N((C 1 -C 6 )alkyl) 2 ,
optionally substituted phenyl, (wherein said optional substitutents on said phenyl are 1 to 3 groups independently selected from OH, CN, —(C 1 -C 4 )alkyl, —(C 1 -C 4 )alkoxyl),
optionally substituted heteroaryl, (wherein said optional substituents on said heteroaryl are 1 to 3 groups independently selected from —(C 1 -C 6 )alkyl, —(C 1 -C 4 )alkoxyl, and cyclopropyl),
optionally substituted cyclopropyl (wherein said optional substituents on said cyclopropyl are 1 to 3 groups independently selected from —(C 1 -C 6 )alkyl), and
optionally substituted heterocycloalkyl (wherein said optional substitutents on said heterocycloalkyl are 1 to 3 groups independently selected from halogen, —OH, oxo, CN, and —(C 1 -C 6 )alkyl,

or, alternatively, R N1 and R N2 are taken together with the nitrogen atom to which they are shown attached to form a 4-, 5-, or 6-membered fully saturated heterocyclic ring comprising (including said nitrogen atom) 1, 2, or 3 ring heteroatoms selected from the group consisting of N, N-oxide, O, S, and S-oxide,
wherein said heterocyclic ring is unsubstituted or substituted with 1, 2, or 3 substituents independently selected from the group consisting of halogen, —OH, oxo, CN, —(C 1 -C 6 )alkyl, amino-substituted —(C 1 -C 6 )alkyl (wherein said amino is 1, 2, or 3 groups independently selected from the group consisting of —NH 2 , —N(C 1 -C 4 alkyl) 2 , and —NH(C 1 -C 4 alkyl)), —O—(C 1 -C 6 )alkyl, —(C 1 -C 6 )alkyl-OH, —(C 1 -C 6 )haloalkyl, —C(O)O—(C 1 -C 6 )alkyl, cyclopropyl, spirocyclopropyl, —NHC(O)O—(C 1 -C 6 )alkyl, —CH 2 —NHC(O)O—(C 1 -C 6 )alkyl, —CH 2 —N(CH 3 )C(O)O—(C 1 -C 6 )alkyl, phenyl, benzyl, —NHC(O)-phenyl, heteroaryl, and —(C 1 -C 4 )alkylheteroaryl, heterocycloalkyl;

Q is a bond or a divalent moiety selected from the group consisting of —C(O)—, —S(O) 2 —, and —C(O)O—; and
R 5 is selected from the group consisting of:
—C(R 5A )(R 5B )(R 5C ), wherein:
each of R 5A and R 5B and R 5C is independently selected from the group consisting of: H, halogen, OH, NH 2 , —(C 1 -C 6 )alkyl, —(C 1 -C 6 )haloalkyl, —(C 1 -C 6 )alkenyl, —(C 1 -C 6 )alkynyl, —(C 3 -C 6 )cycloalkyl, —(C 3 -C 6 )cycloalkyl substituted with —(C 1 -C 6 )alkyl, —(C 1 -C 6 )alkenyl, —(C 1 -C 6 )alkynyl, phenyl, —C(O)phenyl, heteroaryl, heterocycloalkyl, and aryl,
wherein said phenyl, said —C(O)phenyl, said heteroaryl, said heterocycloalkyl, and said aryl are unsubstituted or substituted with from 1, 2, or 3 groups independently selected from halogen, CN, —(C 1 -C 6 )alkyl, —(C 1 -C 6 )haloalkyl, —O—(C 1 -C 6 )alkyl, —O—(C 1 -C 6 )haloalkyl, —C(O)O—(C 1 -C 6 )alkyl, and —N(C 1 -C 6 alkyl) 2 ,

wherein:
n is an integer from 1 to 4; and R 5D is selected from the group consisting of H, —(C 1 -C 6 )alkyl, —(C 1 -C 6 )haloalkyl, phenyl, and phenyl substituted with from 1 to 3 groups independently selected from the group consisting of OH, halogen, —(C 1 -C 6 )alkyl, and —O—(C 1 -C 6 )alkyl, and

benzyl or thienyl, wherein:
said benzyl is unsubstituted or substituted with 1, 2, or 3 groups, and wherein said thienyl is unsubstituted or substituted with 1 or 2 groups, independently selected from the group consisting of halogen, CN, —(C 1 -C 6 )alkyl, —O—(C 1 -C 6 )alkyl, —(C 1 -C 6 )haloalkyl, and —O—(C 1 -C 6 )haloalkyl.

2. The compound of claim 1 , or a pharmaceutically acceptable salt thereof wherein:
Q is a bond or a divalent moiety selected from the group consisting of —C(O)—, —S(O) 2 —, and —C(O)O—; and
R 5 is —C(R 5A )(R 5B )(R 5C ),
each of R 5A and R 5B and R 5C is independently selected from the group consisting of: H, halogen, OH, NH 2 , —(C 1 -C 6 )alkyl, —(C 1 -C 6 )haloalkyl, —(C 1 -C 6 )alkenyl, —(C 1 -C 6 )alkynyl, —(C 3 -C 6 )cycloalkyl, —(C 3 -C 6 )cycloalkyl substituted with —(C 1 -C 6 )alkyl, —(C 1 -C 6 )alkenyl, —(C 1 -C 6 )alkynyl, phenyl, —C(O)phenyl, heteroaryl, heterocycloalkyl, and aryl,
wherein said phenyl, said —C(O)phenyl, said heteroaryl, said heterocycloalkyl, and said aryl are unsubstituted or substituted with from 1, 2, or 3 groups independently selected from halogen, CN, —(C 1 -C 6 )alkyl, —(C 1 -C 6 )haloalkyl, —O—(C 1 -C 6 )alkyl, —O—(C 1 -C 6 )haloalkyl, —C(O)O—(C 1 -C 6 )alkyl, and —N(C 1 -C 6 alkyl) 2 .

3. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein:
Q is —C(O)—;
R 5A is OH or NH 2 ;
R 5B is —(C 1 -C 3 )fluoroalkyl; and
R 5C is selected from the group consisting of:
—(C 1 -C 6 )alkyl, —(C 1 -C 4 )fluoroalkyl, phenyl optionally substituted with 1 to 3 groups, —C(O)phenyl optionally substituted with 1 to 3 groups, cyclopropyl optionally substituted with 1 to 2 groups, cyclobutyl optionally substituted with 1 to 2 groups, thienyl optionally substituted with 1 to 2 groups, pyridyl optionally substituted with 1 to 2 groups, naphthyl optionally substituted with 1 to 3 groups, cyclopentylphenyl optionally substituted with 1 to 3 groups, and benzthiazolyl optionally substituted with 1 to 3 groups,
wherein each said optional substituent is independently selected from halogen —(C 1 -C 6 )alkyl, —(C 1 -C 6 )alkenyl, and —O(C 1 -C 6 )alkyl, and —(C 1 -C 6 )haloalkyl.

4. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein:
Q is a bond or a divalent moiety selected from the group consisting of —C(O)—, —S(O) 2 —, and —C(O)O—; and
R 5 is selected from the group consisting of

wherein n is an integer from 1 to 4; and R 5D is selected from the group consisting of H, —(C 1 -C 6 )alkyl, —(C 1 -C 6 )haloalkyl, phenyl, and phenyl substituted with from 1 to 3 groups independently selected from the group consisting of OH, F, Cl, —(C 1 -C 6 )alkyl, and —O—(C 1 -C 6 )alkyl.

5. The compound according to claim 1 , or a pharmaceutically acceptable salt thereof wherein:
L is —C(O)—; and R 3 is —N(R N1 )(R N2 ), wherein:
R N1 is selected from the group consisting of H and —(C 1 -C 6 )alkyl; and
R N2 is selected from the group consisting of: H, —(C 1 -C 6 )alkyl, —O—(C 1 -C 6 )alkyl,

Assignees

• Merck Sharp & Dohme

Inventors

• Rudd Michael T
• Bennett David Jonathan
• Wai Jenny
• Meng Zhaoyang

Classifications

• C07D211/54

  Sulfur atoms · CPC title

• C07D211/10

  with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms · CPC title

• C07D211/46

  having a hydrogen atom as the second substituent in position 4 · CPC title

• C07D487/08

  Bridged systems · CPC title

• C07D417/14

  containing three or more hetero rings · CPC title